LOS ANGELES, Oct. 19, 2022 (GLOBE NEWSWIRE) — The law firm of Portnoy advises Humanigen, Inc. HGEN Investors that a class action lawsuit has been filed on behalf of investors. Humane investors who have lost money on their investment are encouraged to do so Contact Lesley Portnoy, Esq.

Investors are encouraged to contact an attorney Lesley F Portnoyby phone 844-767-8529 or E-mail: [email protected]to discuss your legal rights, or click here to join the case about www.portnoylaw.com. Portnoy Law Firm can provide a free case assessment and discuss investors’ options for making claims to recover their losses.

According to the Complaint, throughout the Class Period, the Defendants made false and/or misleading statements and/or failed to disclose that: (1) lenzilumab was less effective in treating hospitalized COVID-19 patients than the Defendants argued; (2) As a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve emergency use approval for lenzilumab (“EUA”) and the ACTIV-5/BET-B study was likely to meet its primary endpoint would not achieve; (3) accordingly, the clinical and commercial prospects of lenzilumab have been overstated; and (4) as a result, Humanigen’s public statements were materially false and misleading at all relevant times. As the true details emerged, the lawsuit alleges that investors suffered damage.

Please visit our website to verify further information and to submit your transaction information.

Portnoy Law Firm represents investors in asserting claims against companies caused by wrongdoing. The firm’s founding partner has recovered over $5.5 billion for aggrieved investors. attorney advertising. Previous results do not guarantee similar results.

Lesley F. Portnoy, Esq.
Bar Association in CA and NY
[email protected]
310-692-8883
www.portnoylaw.com
lawyer advertising